U.S. markets open in 6 hours 26 minutes
  • S&P Futures

    4,413.50
    +24.00 (+0.55%)
     
  • Dow Futures

    34,995.00
    +163.00 (+0.47%)
     
  • Nasdaq Futures

    15,041.50
    +85.75 (+0.57%)
     
  • Russell 2000 Futures

    2,241.80
    +20.20 (+0.91%)
     
  • Crude Oil

    73.26
    -0.69 (-0.93%)
     
  • Gold

    1,810.00
    -7.20 (-0.40%)
     
  • Silver

    25.51
    -0.03 (-0.13%)
     
  • EUR/USD

    1.1889
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.2390
    0.0000 (0.00%)
     
  • Vix

    18.24
    +0.54 (+3.05%)
     
  • GBP/USD

    1.3927
    +0.0021 (+0.15%)
     
  • USD/JPY

    109.6400
    +0.0250 (+0.02%)
     
  • BTC-USD

    40,239.34
    -1,492.11 (-3.58%)
     
  • CMC Crypto 200

    977.61
    +27.71 (+2.92%)
     
  • FTSE 100

    7,032.30
    -46.12 (-0.65%)
     
  • Nikkei 225

    27,781.02
    +497.43 (+1.82%)
     

Dynavax to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

·1 min read

EMERYVILLE, Calif., June 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m. E.T.

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:
Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-301309437.html

SOURCE Dynavax Technologies